The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms
In this video, Roman Doll, BSc, MSc, University of Oxford, Oxford, UK, discusses the potential of genome editing for the treatment of JAK2 V617F-driven myeloproliferative neoplasms (MPNs). He highlights that current therapies often fail to eliminate mutant cells, and that genome editing may offer a more potent approach by selectively inactivating the V617F mutant alleles. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
